EUVIMEDEUVIMED entdecken
Crossref

Phosphatidylserine Topically Attenuates Imiquimod-induced Psoriasis Through Inflammation Inhibition in Mice

Bahareh Farasati Far, Partow Mirzaee Saffari, Razieh Mohammad Jafari, Ramin Goudarzi, Ahmad Reza Dehpour, Alireza Partoazar

Drug Research · 01.01.2025 · 75 (01) · 12-20

DOI: 10.1055/a-2419-9616 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Research, erschienen am 01.01.2025. Verfasst von Bahareh Farasati Far und 5 weiteren Autor:innen. Beteiligte Einrichtung: Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Psoriasis, Imiquimod, Disease Models, Animal, Skin. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Psoriasis is a chronic skin condition that is associated with persistent inflammation and skin lesions. Topical therapy has been a promising approach to the alleviation of psoriasis through the application of anti-inflammatory agents. Phosphatidylserine (PS) administration has shown anti-inflammatory effects in the trials. Consequently, the objective of this study was to evaluate the effects of topical PS on the potential improvement of an imiquimod (IMQ)-induced psoriasis model. Additionally, cyclosporine A was utilized as a comparative anti-psoriatic agent in our study.

Methods

The psoriasis model was established by topically applying IMQ to the dorsal skin of mice once daily for five consecutive days. The efficacy of topical PS was assessed using the Psoriasis Area and Severity Index (PASI) score to evaluate skin lesions. Subsequently, the skin samples were analyzed using Baker’s scoring system, Masson’s trichrome staining, immunohistochemistry, and real-time PCR analysis.

Results

IMQ-induced plaque-type psoriasis resulted in a significant increase (P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisImiquimodDisease Models, AnimalSkinPhosphatidylserinesAnimalsMiceCyclosporineCytokinesAnti-Inflammatory AgentsAdministration, TopicalMice, Inbred BALB CInflammationAdministration, CutaneousTumor Necrosis Factor-alphaMale

Substanzen

ImiquimodPhosphatidylserinesCyclosporineCytokinesAnti-Inflammatory AgentsTumor Necrosis Factor-alpha

Autor:innen und Institutionen

  • Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Department of Chemistry, Iran University of Science and Technology, Tehran, Iran.
  • Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • Division of Research and Development, Pharmin USA, LLC, San Jose, CA, United States of America.

Zitieren

APA

Far, B. F., Saffari, P. M., Jafari, R. M., Goudarzi, R., Dehpour, A. R., & Partoazar, A. (2025). Phosphatidylserine Topically Attenuates Imiquimod-induced Psoriasis Through Inflammation Inhibition in Mice. Drug Research, 75(01), 12-20. https://doi.org/10.1055/a-2419-9616

Vancouver

Far BF, Saffari PM, Jafari RM, Goudarzi R, Dehpour AR, Partoazar A. Phosphatidylserine Topically Attenuates Imiquimod-induced Psoriasis Through Inflammation Inhibition in Mice. Drug Research. 2025;75(01):12-20. doi:10.1055/a-2419-9616

BibTeX
@article{Far2025,
  author = {Far, Bahareh Farasati and Saffari, Partow Mirzaee and Jafari, Razieh Mohammad and Goudarzi, Ramin and Dehpour, Ahmad Reza and Partoazar, Alireza},
  title = {Phosphatidylserine Topically Attenuates Imiquimod-induced Psoriasis Through Inflammation Inhibition in Mice},
  journal = {Drug Research},
  year = {2025},
  volume = {75},
  number = {01},
  pages = {12--20},
  doi = {10.1055/a-2419-9616}
}
Kostenlos starten →